deltatrials
Terminated OBSERVATIONAL NCT01148160

Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy

The Correlation of Voriconazole Trough Plasma Levels With Genetic Polymorphism, Efficacy, and Safety Outcomes in Hematologic Malignancy Patients With Invasive Pulmonary Aspergillosis

Sponsor: Asan Medical Center

Interventions voriconazole
Updated 12 times since 2017 Last updated: Apr 9, 2014 Started: Aug 31, 2010 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

This observational or N/A phase trial investigates Invasive Fungal Infection and is currently terminated or withdrawn. Asan Medical Center leads this study, which shows 12 recorded versions since 2010 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Study Description(click to expand)

The investigators are trying to establish that routine clinical practice for voriconazole therapeutic drug monitoring can improve the efficacy and safety outcomes. In Korean patients with hematologic malignancy, the investigators also want to propose the optimal dosing guideline of voriconazole with different genetic polymorphisms.

The investigators are trying to establish that routine clinical practice for voriconazole therapeutic drug monitoring can improve the efficacy and safety outcomes.

In Korean patients with hematologic malignancy, the investigators also want to propose the optimal dosing guideline of voriconazole with different genetic polymorphisms.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotTerminated~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshotTerminated~Apr 2018 – ~May 2018 · 30 days · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 7 months · monthly snapshotTerminated~Jan 2026 – present · 3 months · monthly snapshotTerminated

Change History

12 versions recorded
  1. Jan 2026 — Present [monthly]

    Terminated

  2. Sep 2025 — Present [monthly]

    Terminated

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated

  5. Dec 2021 — Jul 2024 [monthly]

    Terminated

Show 7 earlier versions
  1. Jan 2021 — Dec 2021 [monthly]

    Terminated

  2. Nov 2020 — Jan 2021 [monthly]

    Terminated

  3. Jun 2018 — Nov 2020 [monthly]

    Terminated

  4. May 2018 — Jun 2018 [monthly]

    Terminated

  5. Apr 2018 — May 2018 [monthly]

    Terminated

    Phase: NANone

  6. Aug 2017 — Apr 2018 [monthly]

    Terminated NA

  7. Jan 2017 — Aug 2017 [monthly]

    Terminated NA

    First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Asan Medical Center
Data source: Asan Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations